Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.

Biotechnology

Health & Wellness

Health Care

Pharmaceutical

Amolyt Pharma

Amolyt Pharma's headquarters in Écully, France

Michael Culler

Clémentine Chalmey

Delphine Martinez

Guillaume Ravel, PharmD, PhD, DABT

michel ovize

Benedicte Gagnere

Aurélie MILLERAT

Héloïse Boullet

Laetitia Ouafki

Patrick Loustau

Caroline Robo (Fesquet)

Divya Gupta

Nadege Tremel

Description

People (8)